Key Highlights
- Marc Ballas, M.D. appointed as SVP, head of clinical development.
- Adam Thomas joins as chief people and experience officer.
- Focus on advancing MOMA’s lead precision oncology assets.
- Enhancing MOMA’s physical, digital, and cultural employee experience.
- Strategic vision integral to MOMA’s clinical-stage evolution.
Source: Business Wire
Notable Quotes
- “Marc and Adam both bring deep experience and strategic vision integral to shaping these critical areas of our business during this next stage. I am delighted to welcome them to the leadership team as we drive our projects toward direct impact for patients in need.” — Asit Parikh, M.D., Ph.D., Chief Executive Officer at MOMA Therapeutics
- “The caliber of talent and scientific rigor across the company drew me to this new role as we expand our work into the clinic. I am excited to collaborate with the team as we continue to prosecute our lead candidates, advance our rich portfolio and maximize the potential of our KnowledgeBase platform to deliver breakthrough precision medicines.” — Marc Ballas, M.D., SVP, Head of Clinical Development at MOMA Therapeutics
- “MOMA has one of the most vibrant company cultures I have experienced, guided by a common goal to deliver science with purpose. I am thrilled to work with our talented team to uphold this authentic foundation and help MOMA grow and thrive in our new era as a clinical organization.” — Adam Thomas, Chief People and Experience Officer at MOMA Therapeutics
SoHC's Take
The appointments of Marc Ballas, M.D., and Adam Thomas to MOMA Therapeutics’ leadership team signal a strategic enhancement as the company transitions to a clinical-stage entity. Dr. Ballas’ extensive background in clinical development will be pivotal in advancing MOMA’s precision oncology assets, while Mr. Thomas’ expertise in human resources and organizational development is crucial for fostering a robust company culture and operational excellence. These leadership changes are timely, aligning with MOMA’s trajectory toward filing Investigational New Drug applications and its ongoing collaboration with Roche, positioning the company for significant advancements in the biopharmaceutical landscape.
